Case Report Posterior reversible encephalopathy syndrome in a child with steroid-resistant nephrotic syndrome: a case report and review of literature

Yu Zhang, Jianhua Zhou, Yu Chen

Pediatric Intensive Care Unit, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Received May 21, 2014; Accepted June 28, 2014; Epub June 15, 2014; Published July 1, 2014

Abstract: Posterior reversible encephalopathy syndrome (PRES) is a rare and serious syndrome of central nervous system that can develop in both adults and children. It is characterized by acute onset of headache, confusion, seizures or focal neurological deficits along with radiological findings of white matter abnormalities in the parietal and occipital lobes. In the past ten years, this syndrome has been described mainly in adults, rare in children. Here, we report a case of PRES presenting in a 12-year-old girl with steroid-resistant nephrotic syndrome. Her neurological symptom was rapidly recovered after control of hypertension without discontinuation of cyclosporine A.

Keywords: Posterior reversible encephalopathy syndrome, steroid-resistant nephrotic syndrome, hypertension, cyclosporine A, children

Introduction

Posterior reversible encephalopathy syndrome, a rare disorder of central nervous system, was first described by Hinchey in 1996 [1]. It was defined as a variable combination of consciousness impairment, seizure activity, headaches, vomiting, visual abnormalities (hemianopsia or cortical blindness) and focal neurological signs, which was associated with neuroimaging abnormalities characterized by partially or completely reversible subcortical vasogenic oedema in the posterior white matter [1-6]. PRES can develop in association with a vast array of clinical conditions including autoimmune diseases (such as SLE or Wegener granulomatosis), systemic infections, pre-eclampsia, hypertension, organ transplantation, malignancies, chemotherapy, and immunosuppression (especially with calcineurin inhibitors) [2, 4, 6]. Here, we present a case of PRES in a 12-year-old girl with steroid-resistant nephrotic syndrome.

Case report

A 12-year-old Chinese girl presented with oliguria, severe generalized body edema, proteinuria of 150.2 mg/kg/24 hr, low serum albumin of 9 g/L, high serum cholesterol of 13.2 mmol/L and initial arterial blood pressure of 95/81 mmHg. She was found to have steroid-resistant nephrotic syndrome and kidney biopsy revealed mild mesangial hypercellurity with moderate tubulointerstitial lesions (Figure 1). The girl was treated with steroids and cyclosporine A. On day twenty-one of hospitalization (thirteen days after the initiation of cyclosporine A therapy at a dose of 100 mg twice a day (5.7 mg/kg/day)), while her symptoms were improving, the child developed sudden headache, temporal blindness and generalized tonic clonic convulsion followed by unconsciousness. The blood pressure was 132/97 mmHg, pulse 150 beats per minute and temperature 36.8°C. Neurological examination showed normal cranial nerve function, equal and symmetric deep tendon reflexes. Muscle strength was 3/5 in bilateral upper and lower extremities.

On laboratory evaluation, the child had no evidence of infection. She had massive urinary protein excretion of 150 mg/kg/24 hr, low serum albumin of 18.3 g/L, normal serum urea of 3.44 mmol/L, normal serum creatinine of 34




Figure 1. Renopathological analysis reveals mild mesangial hypercellurity and moderate tubulointerstitial lesions, including degeneration or necrosis of tubular epithelial cells, tubulointerstitial edema.




Figure 2. CT image shows bilateral hypodensities involving gray and white matter in parieto-occipital lobes.

µmol/L and normal serum electrolytes levels. A non-contrast computed tomogoraphy was done on the day of the seizures, and it showed symmetrical hypodensities in parieto-occipital regions of cerebral hemispheres (**Figure 2**). Two days after seizures, magnetic resonance imaging T2 showed hyperintense signal in the parieto-occipital regions, and axial FLAIR images and DWI revealed bilateral cortical and subcortical white matter edema in parieto-occipital lobes (**Figure 3**).

The child was treated with antihypertensive medications (amiodipine besylate and fosino-

pril), anti-seizure medication (levetiracetam), diuretic, steroids and immunosuppressant (cyclosporin A), thereafter she got no seizure and regained full consciousness and vision 5 days later. Her blood pressure was kept at 90/63 mmHg and urinary protein excretion gradually decreased. Follow-up MRI 13 days after seizures demonstrated partial resolution of the initial cerebral lesions (**Figure 4**). She got complete remission of nephrotic syndrome after two months treatment of cyclosporin A.

Discussion

PRES was first described by Hinchey et al in 1996. Over the past decade, with advance in neuroimaging techniques, PRES has been shown to be associated with Henoch-Schönlein purpura, post streptococcal glomerulonephritis, hemolytic uremic syndrome, hypertension, Addison's disease, ganglioneuroma, acute lymphoblastic leukemia, intrabdominal neurogenic tumors, porphyria, bone marrow transplant and steroids in children [7-10]. Clinical features of PRES are typically characterized by headache, vomiting, visual disturbances, confusion, altered sensorium, and seizure. This nephrotic case presented with headache, seizures, blindness, confusion and hypertension, with cyclosporin A treatment. It was similar to previous descriptions in the literature.

The exact pathophysiological mechanism of PRES remains unclear. Three hypotheses have been suggested, which include: first, after exposure to causative agent (such as severe hypertension), autoregulation mechanism of




Figure 3. Magnetic resonance images two days after seizures shows marked hyperintensity in T2 and FLAIR sequences of the parieto-occipital lesions, and restricted diffusion in DWI sequences of the corresponding lesions. Lesions show slight contrast enhancement.




Figure 4. Magnetic resonance images thirteen days after seizures shows partial resolution of the initial cerebral lesions in T2 and T2 FLAIR sequences.

intracranial pressure fails, leading to vasogenic edema; second, after exposure to causative agent (such as mild-to-moderate hypertension), cerebral vasoconstriction and hypoperfusion cause vasogenic brain edema and ischemia; third, endothelial injury with disruption of the blood-brain barrier leads to fluid and protein transudation in the brain [4, 5, 11]. It's speculated that, in this case, sudden elevations in blood pressure, severe hypoalbuminaemia and cyclosporine A administration may be the candidate causes of PRES.

PRES can be diagnosed according to typical clinical manifestation and neurological image examination. Patients are generally presented with headache, vomiting, visual perception abnormalities and seizures, and radiologically characterized by symmetric distribution of patchy or globe-like lesions in the white matter of the parietal and occipital lobes. CT scan, which is usually easier to perform first, shows multiple hypodensities in the cortico-subcortical areas, which is different from acute infarct

or hemorrhage. On magnetic resonance imaging, T1-weighted hypointense, T2-weighted hyperintense and T2-weighted FLAIR hyperintense areas are bilaterally revealed in the occipital and parietal lobes, which can partially or completely resolved on follow-up scans. In general, vasogenic edema is considered to account for the pathophysiology of PRES, but the presence of cytotoxic oedema is the main prognostic factor for the condition as it may signify irreversible brain injury. DWI sequence can be helpful in differentiating between cytotoxic edema and vasogenic edema. In our case, T2-weighted imaging, axial FLAIR imaging and diffusion weighted imaging showed hyperintense signal in the parieto-occipital areas that were partially resolved at 13 days after therapy. DWI hyperintense suggested the patient may have irreversible brain injury.

PRES must be managed carefully, the pathogenic factors should be clarified if possible since remove of etiologies is very important for the successful treatment. In hypertensionrelated and drug-induced PRES, effective management includes prompt withdrawl of offending agent, aggressive control of blood pressure, timely anti-convulsion. Controversy still exists whether immunosuppression should be continued in the treatment of PRES with steroid-resistant nephrotic syndrome. In our case, hypertension was undoubtedly an important cause, but we were uncertain whether cyclosporine A also played a pathogenic role. Considering that extreme hypoalbuminemia may worsen brain edema, and patient could not get remission of nephrotic syndrome without powerful immunosuppression treatment, we continued cyclosporine A and steroid treatment along with prompt anti-hypertension and anti-seizure, and finally the patient got remission of not only PRES but also nephrotic syndrome. It suggests that immunosuppressive agents can be cautiously administrated in steroid-resistant nephrotic patients with PRES. Most PRES cases were fully reversible in a matter of days to weeks, with timely treatment. However, prolonged seizures and hypertension may result in death or permanent neurological disability [12-14]. Therefore, prompt recognition and timely rational management is important to prevent irreversible neurological deficits.

Conclusion

Through our case report and a review of the literature, we wish to highlight that steroid-resistant nephrotic syndrome especially along with hypertension should be considered risk factors for developing PRES in children. An awareness of this observation is crucial for timely diagnosis and treatment, and therefore minimizing the risk of permanent neurologic deficits. Moreover, our case suggests that immunosuppressive agents might be cautiously used in steroidresistant nephrotic syndrome with PRES when patients present with severe edema and extreme hypoalbuminemia.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Yu Chen, Pediatric Intensive Care Unit, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave., Wuhan 430030, P. R. China. Fax: +86-27-83663256; E-mail: yuchenneph@163.com

References

- Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494-500.
- [2] Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008; 65: 205-210.
- [3] Bartynski WS, Tan HP, Boardman JF, Shapiro R, Marsh JW. Posterior reversible encephalopathy syndrome after solid organ transplantation. Am J Neuroradiol 2008; 29: 924-930.
- [4] Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008; 29: 1036-1042.
- [5] Feske SK. Posterior reversible encephalopathy syndrome: a review. Semin Neurol 2011; 31: 202-215.
- [6] Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010; 85: 427-432.
- [7] Kwon S, Koo J, Lee S. Clinical spectrum of reversible posterior leucoencephalopathy syndrome. Pediatr Neurol 2001; 24: 361-364.
- [8] Prasad N, Gulati S, Gupta RK, Sharma K, Gulati K, Sharma RK, Gupta A. Spectrum of radiological changes in hypertensive children with reversible posteriorleucoencephalopathy. Br J Radiol 2007; 80: 422-429.
- [9] Singhi P, Subramanian C, Jain V, Singhi S, Ray M. Reversible brain lesions in childhood hypertension. Acta Paediatr 2002; 91: 1005-1007.
- [10] Gupta S, Goyal VK, Talukdar B. Reversible posterior leucoencephalopathy syndrome in post streptococcal glomerulonephritis. Indian Pediatr 2010; 47: 274-276.
- [11] Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol 2008; 29: 1043-1049.
- [12] Antunes NL, Small TN, George D, Boulad F, Lis E. Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol 1999; 20: 241-243.
- [13] Golombeck SK, Wessig C, Monoranu CM, Schütz A, Solymosi L, Melzer N, Kleinschnitz C. Fatal atypical reversible posterior leukoencephalopathy syndrome: a case report. J Med Case Rep 2013; 7: 14.
- [14] Legriel S, Schraub O, Azoulay E, Hantson P, Magalhaes E, Coquet I, Bretonniere C, Gilhodes O, Anguel N, Megarbane B, Benayoun L, Schnell D, Plantefeve G, Charpentier J, Argaud

L, Mourvillier B, Galbois A, Chalumeau-Lemoine L, Rivoal M, Durand F, Geffroy A, Simon M, Stoclin A, Pallot JL, Arbelot C, Nyunga M, Lesieur O, Troché G, Bruneel F, Cordoliani YS, Bedos JP, Pico F; Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS). Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One 2012; 7: e44534.